KRAS and Cirrhosis: Baseline polymorphisms in NS3 or NS5A had no impact on treatment outcome in patients infected with any GT1, GT2, GT4, GT5, or GT6 subtype, irrespective of treatment duration, prior treatment experience, or cirrhosis status, consistent with the observation that glecaprevir and pibrentasvir retained their in vitro activity against most amino acid substitutions in NS3 and NS5A, respectively, for these genotypes (18, 19).